

SCIENTIFIC REPORTS

OPEN

Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options

Giulia Maria Camerino¹, Adriano Fonzino¹, Elena Conte¹, Michela De Bellis¹, Antonietta Mele¹, Antonella Liantonio¹, Domenico Tricarico¹, Nancy Tarantino¹, Gabriella Dobrowolny^{2,3}, Antonio Musarò^{2,3}, Jean-Francois Desaphy⁴, Annamaria De Luca¹ & Sabata Pierno¹

The discovery of pathogenetic mechanisms is essential to identify new therapeutic approaches in Amyotrophic Lateral Sclerosis (ALS). Here we investigated the role of the most important ion channels in skeletal muscle of an ALS animal model (MLC/SOD1^{G93A}) carrying a mutated SOD1 exclusively in this tissue, avoiding motor-neuron involvement. Ion channels are fundamental proteins for muscle function, and also to sustain neuromuscular junction and nerve integrity. By a multivariate statistical analysis, using machine learning algorithms, we identified the discriminant genes in MLC/SOD1^{G93A} mice. Surprisingly, the expression of CIC-1 chloride channel, present only in skeletal muscle, was reduced. Also, the expression of Protein Kinase-C, known to control CIC-1 activity, was increased, causing its inhibition. The functional characterization confirmed the reduction of CIC-1 activity, leading to hyperexcitability and impaired relaxation. The increased expression of ion channel coupled AMPA-receptor may contribute to sustained depolarization and functional impairment. Also, the decreased expression of irisin, a muscle-secreted peptide protecting brain function, may disturb muscle-nerve connection. Interestingly, the *in-vitro* application of chelerythrine or acetazolamide, restored CIC-1 activity and sarcolemma hyperexcitability in these mice. These findings show that ion channel function impairment in skeletal muscle may lead to motor-neuron increased vulnerability, and opens the possibility to investigate on new compounds as promising therapy.

Amyotrophic Lateral Sclerosis (ALS) is a progressive degenerative disease affecting motor neurons. Because of disrupted nerve-muscle communication, afflicted individuals progressively lose control of voluntary muscle function and experience muscle weakness until paralysis. Many of the familial cases of ALS are due to mutations within the gene encoding the superoxide dismutase 1 (SOD1) protein, involved in the detoxification of reactive oxygen species¹. Despite many advances in the understanding of the genetic causes of ALS, there is no effective treatment available for this devastating disease. It is thus imperative to gain insights in the pathophysiology of ALS. It is recognized that ALS involves tissues other than nerves. Skeletal muscle is one of the earliest impaired tissues in ALS, with fasciculation, force decrease, and atrophy². Indeed, skeletal-muscle-restricted expression of mutant SOD1 gene in MLC/SOD1^{G93A} mice causes progressive muscle atrophy, with a significant reduction in muscle strength, alterations in the contractile apparatus, and mitochondrial dysfunction³⁻⁵. The analysis of molecular pathways revealed that accumulation of oxidative stress triggers intracellular degradation mechanisms. Moreover, alterations of the neuromuscular junction (NMJ) seems to play a significant role in disease progression⁶. Indeed, the very earliest manifestation of disease in both the SOD1^{G93A} mouse model (carrying G93A mutation in SOD1 protein) and ALS patients occurs at the NMJ, where significant levels of denervation can

¹Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70125, Bari, Italy. ²DAHFMO-Unit of Histology and Medical Embryology, Sapienza University of Rome, 00161 Laboratory affiliated to Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Rome, Italy. ³Center for Life Nano Science at Sapienza, Istituto Italiano di Tecnologia, 00161, Rome, Italy. ⁴Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Polyclinic, 70124, Bari, Italy. Giulia Maria Camerino and Adriano Fonzino contributed equally. Correspondence and requests for materials should be addressed to S.P. (email: sabata.pierno@uniba.it)

be observed before the onset of motor neuron degeneration⁷. The analysis of molecular mechanisms involved in NMJ dismantlement revealed a link between Protein Kinase C-theta (PKC-theta) activation and NMJ disintegration⁴. Conversely, trophic factors secreted by myofibers, such as Insulin Like Growth Factor-1 (IGF-1) or Glial-Cell-Line-Derived Neurotrophic Factor (GDNF), can promote motor neuron survival in ALS model through stabilization of NMJ⁸. These observations support the view that this pathology is not solely a neurological disorder but also include a “dying-back” phenomenon, by which motor unit loss and altered muscle function precede the death of motor neurons⁹. In this context, sarcolemma ion channels, such as Cl⁻, K⁺, Na⁺ and Ca²⁺ channels play a crucial role in maintaining muscle function. They are involved in the control of muscle excitability, contraction, and plasticity. Mutations in these channels cause inherited channelopathies¹⁰. For instance, the ClC-1 chloride channel is typically expressed in skeletal muscle and controls resting membrane potential and excitability^{11,12}. It sustains the membrane Chloride Conductance (gCl) at rest and its activity is regulated by the PKC-theta, able to phosphorylate and close the channel, and to maintain a low gCl during the first phase of action potential¹³. Hereditary loss-of-function mutations in the ClC-1 channel are responsible for Myotonia Congenita, a disease characterized by impairment of muscle excitability and relaxation¹⁴. Increased muscle excitability and reduction of gCl are also observed during sarcopenia¹⁵ or hypolipidemic drug adverse effects^{16,17}. The ATP-sensitive potassium (KATP) channels associate muscle cell metabolism and electrical activity, they play an important role in the control of contractility, particularly when cellular energetic is compromised, protecting the tissue against calcium overload and fiber damage. Because ion channels activity and expression can be modified either directly or indirectly by oxidative stress^{15,18,19}, they represent potential targets of ALS pathomechanism. Many studies have focused on the alterations of neuronal excitability in sporadic and familial cases of ALS, due to abnormalities in axonal Na⁺ and K⁺ conductance²⁰. It is widely acknowledged that excitotoxicity is an important contributor to ALS by promoting a neurodegenerative cascade via Ca²⁺-mediated processes²¹. Accordingly, the Na⁺ channel blockers, such as mexiletine, have been tested to promote membrane stabilization and to control ALS symptoms²². However, there are no reports on ClC-1 channel involvement in ALS, a channel exclusively expressed in skeletal muscle. In the light of these considerations, we focused our study on ion channel expression and function in skeletal muscles of transgenic SOD1^{G93A} mice and in muscle specific MLC/SOD1^{G93A} mice (carrying the SOD1^{G93A} mutant gene under the transcriptional control of Myosin Light Chain, MLC, a muscle-specific promoter) to elucidate the mechanisms and to find potential therapeutic targets in ALS.

Results

Gene expression profile in skeletal muscle of SOD1^{G93A} and MLC/SOD1^{G93A} mice. The quantitative Real-Time PCR analysis have been used to detect skeletal muscle alterations due to SOD1 mutation in both SOD1^{G93A} and MLC/SOD1^{G93A} mice with respect to age-matched and strain-matched wild-type (WT). We evaluated the expression of a series of genes involved in skeletal muscle structure and function, encoding for ion channels, their regulatory proteins and subunits, structural proteins, markers of denervation (Supplementary Fig. S1) and phenotype shift (Supplementary Fig. S2), hormones and neurotrophic factors. The involvement of these genes in ALS etiology was evaluated by an accurate multivariate statistical analysis PCA-LDA (Principal Component Analysis and Linear Discriminant Analysis), using both unsupervised and supervised machine learning algorithms, which allowed to identify new potential therapeutic targets.

Expression level of ion channels (ClC-1, Nav1.4, BK, Sur1, Kir6.2, Sur2a, Sur2b), transporters (TauT), pumps (SERCA1, SERCA2), protein kinases (PKC, AMPK), phosphatases (CN), marker of muscle atrophy (Murf1), growth factor (NGF) myokines (irisin, myostatin), and receptors (NMDAR, AMPAR, RyR, Notch1).

In Tibialis Anterior (TA) muscles of SOD1^{G93A} mice at 90 days of age, we found a significant down-regulation of mRNA level of ClC1 chloride channel, potassium channel subunit Sur2b, sodium channel subunit Nav1.4, calcium pump SERCA1, the muscle-secreted hormone irisin, myostatin (Mstn), and Notch1, involved in satellite cell proliferation, with respect to that found in age-matched WT mice (Fig. 1). The mRNA level of PKC-theta, PKC-alpha, SERCA2, Calcineurin (CN), Sur1, and the taurine transporter TauT, was significantly up-regulated with respect to that measured in the age-matched WT animals (Fig. 1). In TA of 130 days-old SOD1^{G93A} mice, a higher number of genes was down-regulated, including ClC1, SERCA1, Big Potassium Channel (BK), major subunit of ATP-sensitive inward-rectifier potassium ion channels (Kir6.2), Sulfonylurea receptors 2a and 2b (Sur2a and Sur2b), Nav1.4, AMP-activated protein kinase (AMPK), Ryanodine receptor 1 (Ryr1), Notch1, nerve growth factor (NGF) and Mstn (Fig. 1). Alongside, the mRNA level of SERCA2 and Sulfonylurea receptor 1 (Sur1) was significantly up-regulated (Fig. 1). In TA muscles of MLC/SOD1^{G93A} we found down-regulation of irisin and Mstn and up-regulation of AMPAR2 and of PKC-theta as compared to the strain-matched WT (Fig. 1).

Multivariate Statistical Analysis of gene expression data. Principal Component Analysis (PCA) and Linear Discriminant Analysis (LDA)

The gene expression dataset was composed of 27 columns representing the expression level of genes normalized to β -Actin (housekeeping gene) and 30 rows representing the analyzed TA muscles. This dataset has been used to perform a PCA calculating 27 eigenpairs of eigenvector-eigenvalue to project in the newly modelled subspace of characteristics. This analysis shows that the first 3 Principal Components (PCs) accounted for about the 2/3 of the total of the variance (Supplementary Fig. S3, Tables S1 and S2). Muscles of SOD1^{G93A} group are well separated from the others (Fig. 2A–C). The selected genes were able to separate well also the less affected MLC/SOD1^{G93A} group from their WT. These observations were evident after analysis of the scatterplots in Fig. 2D. In order to confirm it mathematically, we used the PCA-LDA approach. Thus, training an LDA algorithm, we obtained the contribution of each PC to separate the three pairs of groups: (1) SOD1^{G93A} and their age- and strain-matched controls; (2) MLC/SOD1^{G93A} and their strain-matched controls; (3) MLC/SOD1^{G93A} and SOD1^{G93A}. The three LDA (Fig. 2E) were able to find directions (Linear Discriminant, LD) that well segregate samples. The LD coefficients indicated the importance of each PC to separate groups (Supplementary Table S3). Through linear combination of LD coefficients and the PC weight of each gene transcripts (PCA-LDA




Figure 1. Gene expression changes in SOD1^{G93A} and MLC/SOD1^{G93A} mice. mRNA levels of target genes in Tibialis Anterior (TA) muscles of 90 days-old (A), 130 days old (B) SOD1^{G93A} and (C) MLC/SOD1^{G93A} mice (140 days-old). Data are expressed as Relative Fold Change (FC, calculated as [(Transgenic/ctrl value)-1]) versus the strain- and age-matched controls, of transcript levels performed by Real-Time PCR, for chloride channel CIC1, Protein Kinase C theta (PKC theta), Protein Kinase C alpha (PKC alpha), Ryanodine Receptor 1 (Ryr1), SERCA1, SERCA2, Calcineurin (CN), BK, Kir6.2, Sur1, Sur2, Sur2a, Sur2b, Nav1.4, Nmdar1, Ampar2, Murf1, Irisin, Notch1, TauT, Ampk, Nerve Growth Factor (NGF), Myostatin (Mstn) normalized by β -Actin housekeeping gene, in the 6 experimental groups. Each bar represents the FC \pm S.E.M. Five muscles for each experimental group were analyzed and each muscle was analyzed in triplicate.

pipeline), we computed three lists of discriminant genes (Fig. 3, Supplementary Table 4) showing a high weight in the distinction between groups. Farther from the zero the weight is, the greater its discriminating ability. For the separation of MLC/SOD1^{G93A} and WT, the genes with the higher discriminant power were AMPAR2, PKC-theta, Irisin. For MLC/SOD1^{G93A} and SOD1^{G93A} pairs, the highest discriminant genes were Myosin Heavy Chain-2b (MyHC-2B), Acetylcholine Receptor Subunit alpha-1 (AChRa1), SERCA2, CIC1, Myosin Heavy Chain-2a (MyHC-2A), Nav1.4. For separation between SOD1^{G93A} and WT, the following genes were discriminant: AChRa1, SERCA2, MyHC-2B, MyHC-2A, Notch1, Sur1, Myosin Heavy Chain-1 (MyHC-1), CIC-1.

Hierarchical agglomerative clustering. To confirm the pattern modification of transcript levels, we used a hierarchical agglomerative clustering algorithm (Fig. 4). This analysis showed, in an unsupervised manner, that both genes and muscles segregated into two big different clusters. Also in this case, the clusters segregated muscles belonging to ubiquitously SOD1^{G93A} into (MLC/SOD1^{G93A}) and WT, highlighting that the major part of the variance is due to variation in gene expression level occurring in SOD1^{G93A} mice.

CIC-1 protein expression measured by western blot and immunofluorescence assay in SOD1^{G93A} and MLC/SOD1^{G93A} mice. To better explore on the CIC-1 channel modification in skeletal muscle of ALS mice we analyzed the expression of CIC-1 protein by Western Blot (WB) analysis in TA muscles. We found a significant reduction of CIC-1 expression with respect to WT in both models (Fig. 5A), suggesting that a significant less amount of channel protein contributes to the gCl. Since the mRNA level of CIC-1 gene was not significantly changed in the muscle of MLC/SOD1^{G93A} mice, it seems that post-transcriptional events are involved, i.e. an alteration of translation or a rapid degradation of the protein. We also evaluated, by an immunofluorescence assay, the presence of the CIC-1 in cryosections of TA muscle excised from MLC/SOD1^{G93A} mice and of gastrocnemius muscle from SOD1^{G93A} mice (Fig. 5B) both with high expression level of the transgene². The presence of CIC1 protein in muscle sections was shown by using specific antibodies and no modifications were observed in both situations (Fig. 5B).




Figure 2. Principal Component Analysis (PCA) and Linear Discriminant Analysis (LDA) of PCA scores. Scatterplot of PC score onto the first three selected PC. In (A) are shown PC score on PC1 and PC2, in (B) of PC1 and PC3, in (C) of PC2 and PC3, as 2-dimensional graphs. In (D) a 3-dimensional scatterplot of the same PC scores. Each dot represents the intersection of PC scores of the animal muscles ($n = 30$) onto PC1, PC2 and PC3. PC score are linear combinations of initial gene expression values of target genes and their corresponding loading weights in the considered PC. (E) Linear scatter-plots showing the results of the 3 Linear Discriminant Analysis (LDAs) of the first three PC scores. Red dots are MLC/SOD1^{G93A} muscles Linear Discriminant (LD) scores, green dots are the strain-matched WT LD scores, blue dots are SOD1^{G93A} LD scores and black dots strain-matched WT LD scores. On the top was showed the first LD, that better separates red and green dots representing MLC/SOD1^{G93A} and their WT, respectively. In the middle part, LD that better separates MLC/SOD1^{G93A} and SOD1^{G93A} muscles, shown as red and blue dots, respectively. On the bottom, LD that better separates SOD1^{G93A} and their WT, shown as blue and black dots, respectively.

Functional characterization of the SOD1^{G93A} and MLC/SOD1^{G93A} mouse models. Resting chloride and potassium conductances in Extensor Digitorum Longus (EDL) muscle of SOD1^{G93A} and of MLC/SOD1^{G93A} mice and effects of *in vitro* application of chelerythrine and acetazolamide

We measured the resting component conductances (gCl and gK: Potassium Conductance) in EDL muscle of both ALS mouse models. In detail, SOD1^{G93A} muscle fibers showed a significant reduction of gCl with respect to their strain- and age-matched controls by $-27.8 \pm 4.2\%$ and $-33.9 \pm 3.8\%$, at 90 and 130 days of age, respectively (Fig. 5C,D). Thus, a reduction of this parameter was already present at clinical onset, and was more severe at the exacerbation of the signs of pathology. A slight increase of gK (by $+32.8 \pm 11.9\%$) was found in 90 days-old SOD1^{G93A} animals with respect to their controls, while the difference was significant (by $+67.5 \pm 27.9\%$)




Figure 3. PCA/LDA Discriminant Genes. Barplots of Linear Discriminant loading weights of each gene in the three PCA-LDA analysis performed. Each bar represents the weight of the variable in order to discriminate between: (on the left) MLC/SOD1^{G93A} vs. strain matched WT, (in the middle) MLC/SOD1^{G93A} vs. SOD1^{G93A} and (on the right) SOD1^{G93A} vs. strain-matched WT PCA scores. On the right, a legend showing the colors-code to identify the mRNA LD gene loading weight of the target genes. Arrows indicates the most affected genes.




Figure 4. Hierarchical agglomerative clustering of gene expression data. Heatmap of unsupervised machine learning algorithm to perform clusterization of muscles based on gene expression levels. TA muscles and mRNA levels segregated into two principal clusters also in this case, as showed by hierarchical dendrograms of rows and columns. Each square represents the standardized gene expression level normalized with β -actin housekeeping gene in TA muscle of target genes. The columns report target genes, rows report the analysed muscles. Genes and muscles are sorted by hierarchical agglomerative clustering algorithm. Plotted data consists of the entire dataset of animals (SOD1^{G93A}, MLC/SOD1^{G93A} and their strain-matched WT as control).

in 130 days-old SOD1^{G93A} mice (Fig. 5F). In MLC/SOD1^{G93A} mice, we found a significant reduction of gCl by $-22.3 \pm 3.2\%$ with respect to the WT (Fig. 5E). However, no significant differences of gK were observed (Fig. 5G). No modification was found in gCl and gK measured in slow-twitch SOLEUS (SOL) muscles of SOD1^{G93A} and WT at 130 days of age (Supplementary Fig. S4). To evaluate the involvement of the PKC in the reduction of gCl we tested the effect of chelerythrine, a selective inhibitor of PKC²³. We found a significant restoration of gCl in EDL fibers of SOD1^{G93A} mice at both ages and of MLC/SOD1^{G93A} mice after *in vitro* application of chelerythrine




Figure 5. CIC-1 chloride channel expression and activity in MLC/SOD1^{G93A} and SOD1^{G93A} mice. **(A)** Representative Western blot showing the expression level of CIC-1 protein in TA muscle tissue of SOD1^{G93A} and MLC/SOD1^{G93A} mice. The blots were reacted with specific antibodies. β-actin was used to normalize the blot. Gel images are cropped from the blot shown in the Supplementary Figs S7 and S8. Histograms show quantification of relative protein levels calculated by normalization of the absolute intensity of target protein with the absolute intensity of β-actin, as reference standard, and are represented as arbitrary units (AU). Each bar represents the mean ± SEM from five muscles. * Significantly different with respect to WT (at least $P < 0.05$) by Student's t-test. **(B)** Immunofluorescence assay in TA muscle of MLC/SOD1^{G93A} and WT mice and in Gastrocnemius muscle of SOD1^{G93A} mice and WT. The presence of CIC-1 protein in muscle section was shown by specific antibodies. The images are 20X magnification. **(C–G)** The component ionic conductances measured in EDL muscle of SOD1^{G93A} and MLC/SOD1^{G93A} animals. Values are expressed as mean ± S.E.M. from five animals for each experimental condition (10–46 fibers were analyzed in each group of animals). **(C,D)** The macroscopic Chloride Conductance (gCl) measured in EDL muscles fibers of SOD1^{G93A} animals at the two selected ages and effects of the *in-vitro* application of chelerythrine (1 μM). Statistical analysis was performed using one-way ANOVA followed by Bonferroni post-hoc t-test ($F = 15.8$, $df = 2$, $P < 0.0001$, for gCl in SOD1^{G93A} at 90-days) ($F = 16.6$, $df = 2$, $P < 0.0001$ for gCl in SOD1^{G93A} at 130-days). *Significantly different vs. age-matched WT (at least $P < 0.05$). **(E)** Macroscopic gCl measured in EDL muscles fibers of MLC/

SOD1^{G93A} animals and effect of *in-vitro* application of Chelerythrine (1 μ M) or Acetazolamide (ACTZ, 50 μ M). Statistical analysis was performed using one-way ANOVA followed by Bonferroni post-hoc t-test ($F = 12.5$, $df = 3$, $P < 0.0001$, for gCl in MLC/SOD1^{G93A}). *Significantly different vs. age-matched WT (at least $P < 0.05$). °Significantly different vs. MLC/SOD1^{G93A} (at least $P < 0.05$). (F) The macroscopic Potassium Conductance (gK) measured in EDL muscle fibers of SOD1^{G93A} animals at the two selected ages ($F = 5.18$, $df = 3$, $P < 0.005$, for gK in SOD1^{G93A}). *Significantly different vs. age-matched WT (at least $P < 0.05$). (G) The macroscopic gK measured in EDL muscle of MLC/SOD1^{G93A} mice (no significant differences were found).

(Fig. 5C–E). In addition, we tested the effects of acetazolamide (ACTZ), an inhibitor of carbonic anhydrase, which has been previously shown to increase heterologously-expressed CIC-1 channel activity^{11,14}. Importantly, the *in vitro* application of ACTZ led to an increase of gCl in EDL muscle fibers of MLC/SOD1^{G93A} mice toward the WT value (Fig. 5E) suggesting potential beneficial effects in ALS models characterized by gCl reduction and hyperexcitability.

Excitability parameters in EDL muscle of SOD1^{G93A} and MLC/SOD1^{G93A} mice. The excitability parameters were recorded in EDL muscle of SOD1^{G93A} mice and in muscle specific MLC/SOD1^{G93A} transgenic mice. Representative traces of the active parameters measured in EDL muscle of SOD1^{G93A} mice and relative WT, are shown in Fig. 6(A–D). In accord with the reduction of gCl the excitability parameters were modified (Fig. 6E–H). In particular, the Latency of action potential (Lat, the delay from the beginning of the current pulse to the onset of an action potential at threshold, in milliseconds) was increased in SOD1^{G93A} mice at 90 and at 130 days of age ($+117.7 \pm 29.9\%$ and $+87.7 \pm 20.8\%$, respectively) with respect to their age-matched WT. The threshold current for the onset of the first action potential (Ith, in nanoamperes) was decreased at both age-points ($-64.8 \pm 5.6\%$ and $-44.4 \pm 9.6\%$, respectively) and the maximum number of elicited spikes was increased ($+55.4 \pm 15\%$ and $+77.5 \pm 18\%$, respectively). Also, we found a decrease of the amplitude (AP, in millivolts) of action potential (by $-22.1 \pm 6.3\%$) only at 130 days of age. The excitability parameters of sarcolemma have been measured also in EDL muscle fibers of MLC/SOD1^{G93A} mice and their strain-matched controls (Fig. 6I). In general, active parameters of MLC/SOD1^{G93A} mice were less affected with respect to SOD1^{G93A} ones. Indeed, only the maximum number of elicited spikes was significantly increased by $+72.3 \pm 11.7\%$ with respect to WT. Importantly, the application of 50 μ M ACTZ significantly restored the maximum number of spikes toward control value.

ATP-sensitive potassium channels (KATP) activity in skeletal muscle of SOD1^{G93A} mice. Patch-clamp experiments were performed on fast-twitch flexor digitorum brevis (FDB) muscle fibers to test whether the ubiquitous expression of SOD1^{G93A} can modify the activity of KATP channels, which are known to be altered during various physiopathological conditions²⁴. The current amplitude of the KATP channel was increased in the FDB muscle of SOD1^{G93A} mice with respect to WT at 130 days (Fig. 7A). Exposure of macro-patches to intracellular ATP (100 μ M–5 mM) greatly reduced the current amplitude in control conditions, confirming that these currents flowed through KATP channels (Fig. 7B). However, KATP channels of SOD1^{G93A} mice were less sensitive to 100 μ M ATP.

Calcium Homeostasis and response to caffeine in skeletal muscle of SOD1^{G93A} and of MLC/SOD1^{G93A} mice. Using the FURA-2 cytofluorimetric technique, we measured calcium homeostasis in EDL muscle fibers of SOD1^{G93A} and MLC/SOD1^{G93A} mice in comparison to strain-matched WT (Fig. 8, B). Muscle fibers of SOD1^{G93A} mice showed a significant increase in resting cytosolic calcium (restCa) concentration with respect to WT. *In-vitro* application of 40 mM caffeine, a modulator of RyR, on EDL fibers of SOD1^{G93A} mice, induced a slight increase of restCa suggesting higher sensitivity to the compound (Fig. 8C, D). The restCa level was not significantly modified in skeletal muscle of MLC/SOD1^{G93A} mice.

Discussion

In this study we tested for the first time the activity and expression of various skeletal muscle ion channels, which are pivotal for the function of muscle and of neighboring tissues. The analytical strategy performed allowed the identification of skeletal muscle expression signature, based both on differential gene expression and on gene correlation networks. The results show a clear-cut segregation of muscles in separated groups: SOD1^{G93A} and MLC/SOD1^{G93A} versus their strain-matched WT. The PCA analysis of gene expression data showed no separation between 90 days-old and 130 days-old animals suggesting that skeletal muscle is severely involved in ALS pathogenesis already before the appearance of clear symptoms. In ALS patients, muscle denervation and abnormal reinnervation are pathological hallmarks of the disease. Similarly, an up-regulation of denervation markers (Nav1.5, AChR)^{8,25,26} was found in SOD1^{G93A} muscles at both time points, together with an increase of myogenin^{27–29} that indicates muscle reinnervation process²⁷. In addition, inhibition of Mstn, a negative regulator of muscle mass, suggests an attempt of the muscle to counteract atrophy and promote regeneration. Interestingly, Mstn expression was decreased also in MLC/SOD1^{G93A} mice, the animal model expressing the SOD1 mutant gene selectively in skeletal muscle⁴, again suggesting the early involvement of skeletal muscle in the pathogenesis of ALS. A fast-to-slow phenotype transition was observed in SOD1^{G93A} mice, likely as an attempt to convert muscle fibers into a more resistant slow type, less affected by the pathology. In skeletal muscles of these mice, the expression of CIC-1 channel and the related resting gCl were significantly decreased with respect to WT, at 90 and 130 days of life. This is in accord with the fast-to-slow phenotype transition, since CIC-1 expression and resting gCl in slow-twitch muscles are lower than in the fast ones³⁰. The CIC-1 protein expression and resting gCl were




Figure 6. Sarcolemma excitability parameters measured in EDL muscle of SOD1^{G93A} and MLC/SOD1^{G93A} animals. (A–D) Representative traces of the Action Potential (AP) recorded in EDL muscle fibers by standard two microelectrodes technique at 0.05 mm distance between electrodes, in response to depolarizing square-wave current pulse. (A,B) images showed traces recorded in EDL fibers of WT animals. (C,D) showed the traces recorded in SOD1^{G93A} mice. On the left, it has been used a minimal squared-wave current pulse to elicit the single AP. On the right it has been used the minimum pulse to elicit the maximum number of spikes. (E–H) Excitability parameters of EDL muscle fibers of SOD1^{G93A} animals at 90 and 130 days of age. Values are expressed as mean \pm S.E.M from 10–16 fibers. In (A) the AP amplitude, in (B) the latency time of AP, in (C) the threshold current needed to elicit a single AP (I_{th}) and in (D) the maximum number of elicitable spikes (Max N spikes). Statistical analysis was performed using one-way ANOVA followed by Bonferroni post-hoc t-test ($F = 3.8$, $df = 3$, $P < 0.02$ for AP; $F = 10.06$, $df = 3$, $P < 0.0001$, for Lat; $F = 18.2$, $df = 3$, $P < 0.0001$, for I_{th}; $F = 8.1$, $df = 3$, $P < 0.0001$ for N spikes). *Significantly different vs. age-matched control group (at least $P < 0.05$). (I) Excitability parameters of EDL muscle fibers of MLC/SOD1^{G93A} animals. Values are expressed as

mean \pm S.E.M. from 10–20 fibers. The excitability parameters were recorded in the absence and in the presence of 50 μ M ACTZ. To note, because of the Log scale, the measure units are omitted and are: for Action Potential amplitude (AP) mV; for the threshold current amplitude (Ith) nA; for the latency of AP (Lat) msec; and for the maximum number of elicitable AP (N spikes). Statistical analysis was performed using one-way ANOVA followed by Bonferroni post-hoc t-test ($F = 26.86$, $df = 2$, $P < 0.0001$, for N spikes). *Significantly different vs. WT ($P < 0.05$) °Significantly different vs. MLC/SOD1^{G93A} ($P < 0.05$).

significantly reduced also in muscles of MLC/SOD1^{G93A} mice, likely through a mechanism involving Reactive Oxygen Species (ROS) production. An in-depth analysis revealed that the reduction of gCl in both models also involved PKC-theta up-regulation, which phosphorylates and inhibits the CIC-1 channel^{13,31}. According to the reduction of gCl, sarcolemma excitability was increased, with a significant increase of the maximum number of spikes. The situation was more complex in SOD1^{G93A} mice, since other channels were involved. In these mice a decreased amplitude of the action potential observed in SOD1^{G93A} mice can be in part explained by the down-regulation of Nav1.4 sodium channel transcript. The increase in resting gK is likely sustained by the increased KATP current in SOD1^{G93A} mice, although we cannot exclude the contribution of other K channels. The KATP current is myoprotective and may be activated to dampen excitability. However, the mRNA expression of the pore subunit Kir6.2 and the auxiliary subunit SUR2A was decreased, but it is possible that the increased expression of SUR1, more resistant to oxidative stress, may account for the increased KATP current. Moreover, the modification of the channel and/or the phenotype shift³² may explain the ATP resistance in these mice. All these modifications were not observed in the MLC/SOD1^{G93A} mice. Likewise, calcium channels were strongly involved in the modification of skeletal muscle function in SOD1^{G93A} mice. The restCa was significantly increased in the EDL muscles according to the fast-to-slow phenotype transition. Despite a reduction of RyR mRNA expression, a strong decrease of SERCA1, responsible for SR calcium reuptake, may contribute to the increase of restCa. Also a depletion of ATP may reduce SERCA1 activity. Interestingly, the increase of SERCA2 expression may represent an attempt to compensate for the loss of SERCA1^{33–35}. In MLC/SOD1^{G93A} model, the not significant increase of restCa and the unchanged expression of RyR and SERCA1, both suggest a minor involvement in this strain. Other studies³⁶ have shown an impairment of EC coupling in FDB fast-twitch fibers of both models. All the modifications observed in skeletal muscle of SOD1^{G93A} animals seems to be associated to denervation and phenotype transition. In contrast, no sign of morphological denervation was found in MLC/SOD1^{G93A} mice, at the examined age, where motor neurons are not affected. However muscle restricted expression of SOD1^{G93A} displays alteration in NMJ⁴. MLC/SOD1^{G93A} muscles were characterized by a minor number of transcriptional modifications, and the identified most discriminant genes involved in the onset of damage were PKC-theta, that control muscle CIC-1 activity, AMPAR2, the ionotropic glutamate receptor involved in synaptic plasticity, and irisin, a recently-discovered hormone secreted by skeletal muscle and able to communicate in a paracrine and endocrine manner with nervous system³⁷. The functional significance of an increase of AMPAR2 may be the facilitation of glutamate-induced prolonged depolarization and modulation of messengers (e.g. NO) able to activate retrograde potentiation in pre-synaptic compartments^{38,39}. The consequent muscle hyperexcitability may rapidly exacerbate the damage at neuronal tissue⁹, already compromised by the increase of firing rates, ionic imbalance and sustained depolarization that decreases ATP level^{21,35}. The results indicate that muscle hyperexcitability is due to CIC-1 expression reduction and increased activity of PKC-theta with consequent gCl reduction in MLC/SOD1^{G93A} mice. The increased activity of PKC was confirmed by the *in-vitro* effects of chelerythrine, a well known inhibitor of PKC, which was able to increase the resting gCl²³. Also, AMPAR2 activation can be modulated by PKC-induced increased phosphorylation⁴⁰. Our hypothesis is that selective accumulation of mutant SOD1 in muscle and consequent oxidative stress may affect PKC, ion channel function, and neuromuscular communication⁴¹. In this situation, a “feedback-loop” could be triggered, which may explain why motor neuron death begins with an initial distal hyperexcitability^{42–44}. Accordingly, muscle-specific expression of local Igf-1 (mIgf-1) was shown to stabilize NMJ, reduce inflammation in the spinal cord, and enhance motor neuronal survival in SOD1^{G93A} mice, thereby delaying the onset and progression of the disease^{5,8}. We already demonstrated that Igf-1 signaling is important to maintain a normal phosphatase activity that counterbalances the inhibitory activity of PKC on CIC-1^{45,46}. Thus, it is likely that the decrease of phosphatase activity together with PKC activation strongly contribute to gCl reduction and hyperexcitability in ALS. Since gCl is strongly reduced during aging in skeletal muscle of rodents¹², it is possible that more severe alterations in MLC/SOD1^{G93A} mice may occur at advanced age, as already observed⁵. Accordingly, preliminary data showed a more severe reduction of gCl in 10-months-old MLC/SOD1^{G93A} mice (Supplementary Fig. S6). All these findings identify ACTZ as a potential drug for ALS therapy. As already demonstrated^{11,14,47,48}, this carbonic anhydrase inhibitor, was able to increase CIC-1 channel activity likely through modification of internal pH. The increased expression of carbonic anhydrase in motor neurons of ALS patients also supports ACTZ therapeutic proposal⁴⁹. Notwithstanding the encouraging results in the restoration of gCl and attenuation of muscle hyperexcitability in MLC/SOD1^{G93A} mice, additional preclinical studies are required to better assess the long-term effects of ACTZ. Irisin is another discriminant gene, found to be down-regulated in MLC/SOD1^{G93A} mice. Irisin is a myokine secreted by both skeletal muscle and brain. Physical activity modifies plasma concentration of this hormone known to stimulate the synthesis of brain-derived neurotrophic factor (BDNF) in the nervous system⁵⁰. Thus, irisin associates skeletal muscle activity to that of nervous system in a centripetal manner, being able to cross the blood–brain barrier⁵¹. Irisin gene expression was modified not only in the MLC/SOD1^{G93A} mice, but also in SOD1^{G93A} mice, suggesting that its modification is an early and long-lasting event in the pathogenesis of ALS. Based on these results, irisin may represent a critical link between muscle and CNS in ALS and a likely pharmacological target. Thus, a combined therapy with irisin may be also considered to restore muscle-nerve communication. ACTZ, which increases CIC-1 activity, and riluzole, which




Figure 7. KATP channel current density from WT and SOD1^{G93A} mice measured by patch clamp technique. Each bar is the mean \pm SEM from the number of patches indicated in brackets. **(A)** significant difference among groups was found by one-way ANOVA analysis ($F = 7.2$; $P < 0.0002$). Bonferroni post hoc correction for individual differences between groups is as follows: significantly different * vs WT 130 days ($P < 0.002$); # vs SOD1^{G93A} 90 days ($P < 0.002$). **(B)** Exposure of macropatches to intracellular ATP (100 μM –5 mM) induce a KATP current inhibition. The response of KATP channels to 100 μM ATP is changed in 130 days-old SOD1^{G93A} mice.

inhibit Na⁺ channels activity¹⁴, might act synergically to restore muscle excitability. Our results strengthen the evidence for the role of skeletal muscle in ALS pathogenesis and pave the way for the development of new therapeutic options to hamper the clinical effects of the disease.

Material and Methods

Animal care. In this study two different animal models of ALS were evaluated. Male SOD1^{G93A} transgenic mice ubiquitously expressing the human mutant SOD1 G93A allele containing the Gly93RAla (G93A) substitution were used at two time points (90 and 130 days-old) based on the criteria for disease progression⁵² as clinical onset (mice selected showed no overt sign of pathology) and early symptomatic (mice were selected at abnormal gait and before paralysis). Male MLC/SOD1^{G93A} mice (140 days-old) overexpressing the mutant SOD1^{G93A} transgene under the transcriptional control of the Myosin Light Chain (MLC) muscle specific promoter, so that its expression is selectively restricted in skeletal muscle⁴. Transgenic animals were identified by PCR amplification of DNA extracted from tail tissue⁴⁴. Age-matched C57BL/6J and FVB/NJ mice (Jackson Laboratories, Bar Harbor, ME, USA) were used as WT control strain, respectively. The animals were housed in a temperature-controlled (22 °C) room with a 12:12 h light-dark cycle. Before muscle dissection animals were deeply anesthetized with ketamine (100 mg/kg ip)/xylazine (16 mg/kg ip). The experiments were approved by the ethics committee of the University of Bari and by the Veterinary authority of the Italian Ministry of Health (D.M. n.126/2009, Authorization 386/2017-PR) and were performed in accordance with the Italian Guidelines for the Use and Care of Laboratory Animals (D. Lgs 2014 n26), which conforms with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and Guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.

Isolation of total RNA, reverse transcription and real-time quantitative polymerase chain reaction (PCR) analysis. Immediately after surgery, TA muscles were snap frozen in liquid nitrogen and stored at -80°C until isolation of total RNA, reverse transcription and real-time PCR analysis, as detailed in Camerino *et al.*¹⁶. Genes were analysed by the use of TaqMan Hydrolysis primer and probe gene expression assays that are produced by Life-Technologies with the following assay IDs: PKC theta (encoded by *Prkca* gene) assay ID: Mm00436796_m1; PKC alpha (encoded by *Prkca* gene) assay ID: Mm00440858_m1; Kir 6.2 (encoded by *Kcnj11* gene) assay ID: Mm00440050_g1; Sur1 (encoded by *Abcc8* gene) assay ID: mm008003450_m1; Ryr1 (encoded by *Ryr1* gene)




Figure 8. Cytosolic resting calcium (restCa) level in EDL muscle fibers measured by FURA-2 cytofluorimetric technique. RestCa level measured in (A) 130 days-old SOD1^{G93A} animals and in (B) 140 days-old MLC/SOD1^{G93A} animals. *Significantly different with respect to WT animals ($P < 0.05$ by Unpaired Student t-test). (C) Representative traces showing a 40 mM caffeine-induced increase of restCa in WT (black trace) and in SOD1^{G93A} (gray trace) mice. (D) Correspondent barplot constructed using the mean values \pm S.E.M. obtained from 15–20 fibers. (E) Schematic representation of the decreased expression of RyR1 and SERCA1 mRNA (black arrows) responsible for the cytosolic calcium increase. Although the decreased expression of RyR in SOD1^{G93A} may indicate the reduction of Ca flux from SR to the cytosol, SERCA reduction slow down the reuptake in the SR. Slight modification in restCa level were observed in MLC/SOD1^{G93A} animals in line with the lack of changes in RyR and SERCA expression.

assay ID: Mm01175211_m1; Nav1.4 (encoded by *Scn4a* gene) assay ID: Mm01258366_m1; Nav1.5 (encoded by *Scn5a* gene) assay ID: Mm01342505_m1; Serca1 (encoded by *Atp2a1* gene) assay ID: Mm01275320_m1; Serca2 (encoded by *Atp2a2* gene) assay ID: Mm01201431_m1; CN (Calcineurin, encoded by *Ppp3ca* gene) assay ID: Mm01317678_m1; Irisin (encoded by *Fndc5* gene) assay ID: Mm01181543_m1; Nmdar1 (encoded by *Grin1* gene) assay ID: Mm00433790_m1; Ampar2 (encoded by *Gria2* gene) assay ID: Mm00442822_m1; Notch1 (encoded by *Notch1* gene) assay ID: Mm00435249_m1; TauT (encoded by *Slc6a6* gene) assay ID: Mm01264789_m1; Murf-1 (encoded by *Trim63* gene) assay ID: Mm01185221_m1; Mhc1, myosin heavy chain 1 (encoded by *Myh7* gene) assay ID: Mm00600555_m1; Mhc2a, myosin heavy chain 2a (encoded by *Myh2* gene) assay ID: Mm00454982_m1; Mhc2b, myosin heavy chain 2b (encoded by *Myh4* gene) assay ID: Mm01332541_m1; Mhc2x, myosin heavy chain 2 \times (encoded by *Myh1* gene) assay ID: Mm01332489_m1; Ampk (encoded by *Prkaa1* gene) assay ID: Mm0164789_m1; Acetylcholine Receptor, Nicotinic, Alpha 1, Achr1 (encoded by *Chrna1* gene) assay ID: Mm00431629_m1; Ngf (encoded by *Ngf* gene) assay ID: mm00443039_m1; Myostatin (encoded by *Mstn* gene) assay ID: Mm01254559_m1; Beta-2-Microglobulin, B2m (encoded by *B2m* gene) assay ID: Mm00437762_m1. For β -actin (*Actb* gene) we designed primer For: 5'-CCAGATCATGTTTGGAG ACCTTCAA-3, primer Rev: 5'-CATACAGGGACAGCACAGCCT-3, probe: VIC-ACC CCA GCC ATG TAC GTAMGB. For chloride channel CIC-1 (*Cln1* gene) we designed

primer For: 5'-TCATGCTCGGTGTCCGAAA-3', primer Rev: 5'-CAGGCGGTGCTTAGCAAGA-3', probe: 6-FAM-ATTGGCTGAGACACTTGT-MGB. For BK channel (*Kcnma1* gene) we designed primer For: 5'-GATATCCGCCAGACACTGAC-3', primer Rev: 5'-AGTATATTACGAGGGGACCAA-3', probe: VIC-CAGAGTCCTGGTTGTGTTA-MGB; For Sur2a (*Abcc9* splicing A gene) we designed primer For: 5'-ACATGGCCACGGAAAACATT-3', primer Rev: 5'-ACTCCACTAAAATACCCTCAGAAAAGA-3', probe: FAM-CCATAGCTCACCGTGTCT-MGBQ; For Sur2b (*Abcc9* splicing B gene) we designed primer For: 5'-CGGATCGACGGTCGTA-3', primer Rev: 5'-TAACCAGGTCTGCAGTCAGAATG-3', probe: FAM-CATAGCTCATCGGGTTC-MGBQ⁵³. The mRNA expression of the genes was normalized to the best house-keeping gene: *Actb* selected from *B2m* and *Actb* by Normfinder software¹⁶. For genes that are poorly expressed, such as *Ampar2*, *Nmdar1*, *Notch1*, *Ngf*, *Mstn* pre-amplification by TaqMan PreAmp Master Mix (Life Technologies C.N. 4391128) was made before the real-time experiments.

Western Blot analysis. CIC1 protein was isolated from TA muscle of MLC/SOD1^{G93A} and processed as described in Camerino *et al.*¹⁶. Primary rabbit anti-CIC1 antibody (MyBiosource) was diluted 1:200 with TBS containing 5% non-fat dry milk overnight. Membranes were incubated for 1 h with secondary antibody labeled with peroxidase (1:5000 anti rabbit IgG, Sigma-Aldrich), developed with a chemiluminescent substrate (Clarity Western ECL Substrate, Bio-Rad) and visualized on a Chemidoc imaging system (Bio-Rad). Densitometric analysis of each experimental band was performed using Image Lab software (Bio-Rad). The software allows the chemiluminescence detection of each experimental protein band to obtain the absolute signal intensity. The density volume was automatically adjusted by subtracting the local background. For each sample, the relative intensity was calculated by normalizing the intensity of β -actin protein band (diluted 1:300, rabbit Anti Actin, Santa Cruz Biotechnology) as reference standard.

Immunofluorescence. TA muscles, covered with tissue-tek O.C.T. (Bio-Optica), were frozen in isopentane cooled in liquid nitrogen in a slightly stretched position and stored at -80°C . Serial cross sections (8- μm thick) were cut in a cryostat microtome set a -20°C (Thermo Scientific) and incubated with primary antibody against rabbit CIC-1 diluted 1:100 (MyBiosource) in PBS-gelatin for 1 h. After washing with PBS-gelatin, the sections were incubated with 488-donkey anti rabbit IgG (Invitrogen), diluted 1:1000 in PBS-gelatin for 1 h, then washed with PBS-NaCl (300 mM). Sections were examined using Olympus CX41 microscope⁵³.

Recordings of Resting Chloride and Potassium Conductances and Excitability Parameters in skeletal muscle of SOD1^{G93A} and in muscle specific MLC/SOD1^{G93A} transgenic mice measured in current clamp mode by the Two-Intracellular Microelectrodes Technique. Extensor Digitorum Longus (EDL) and Soleus (Sol) muscles were fixed by tendons to a glass rod immersed in normal (NP) or chloride-free physiological solution maintained at 30°C and perfused with 95% O₂/5% CO₂²³. The NP solution contained (in mM): NaCl 148, KCl 4.5, CaCl₂ 2.0, MgCl₂ 1.0, NaHCO₃ 12.0, NaH₂PO₄ 0.44, glucose 5.5, and pH 7.2. The chloride-free solution was prepared by equimolar substitution of methylsulfate salts for NaCl and KCl and nitrate salts for CaCl₂ and MgCl₂. The cable parameters of myofiber sarcolemma were determined from the electrotonic potentials elicited by square wave hyperpolarizing current pulse of 100-ms duration, using two intracellular microelectrodes in current-clamp mode, as previously described^{30,31,54}. The membrane conductance is calculated from the values of input resistance, space constants and time constant and assuming a myoplasmic resistivity of 125 Ω cm. The mean chloride conductance (gCl) is calculated as the mean total membrane conductance (gm) measured in NP solution minus the mean potassium conductance gK measured in chloride-free solution. Sarcolemma excitability parameters were determined by applying 100ms-long depolarizing current pulses of increasing amplitude to elicit first a single action potential (AP) then a train with the maximal number of APs. The membrane potential was held at -80 mV between test pulses. A single and a train of action potentials were generated by increasing current intensity in the same fiber and the excitability characteristics were measured (amplitude of action potential, threshold current, latency of action potential and N spikes)^{31,55}.

Measurement of KATP channel activity in skeletal muscle of SOD1^{G93A} and in muscle specific MLC/SOD1^{G93A} transgenic mice using whole-cell patch-clamp technique. Patch-clamp experiments were performed on freshly enzymatically dissociated FDB muscle fibers in inside-out configurations using the standard patch-clamp technique. The ATP-sensitive potassium (KATP) channel currents were recorded immediately after excision during voltage steps from 0 to -60 mV with 150 mM KCl on both sides of the membrane patches in the absence (control) or the presence of ATP in the muscle bath²⁴. The currents were recorded at a 1-kHz sampling rate (filter = 0.2 kHz) using an Axopatch-1D amplifier equipped with a CV-4 head stage (Axon Instruments, Union City, CA). Macropatches having an average pipette area of 11.3 ± 1 μm^2 were used to measure the mean KATP currents, which were calculated by subtracting the baseline level from the open-channel level of each current trace and then digitally averaging all generated files using CLAMPFIT (Axon Instruments). The baseline level for the KATP current was measured in the presence of internal ATP (5×10^{-3} M). Current amplitude was measured using CLAMPFIT.

Fluorescence Measurements of Resting Intracellular Ca²⁺ Concentration in skeletal muscle of SOD1^{G93A} and in muscle specific MLC/SOD1^{G93A} transgenic mice using FURA-2 imaging technique. Fluorescence measurements were performed on small bundles of five to ten fibers lengthwise dissected from mice EDL muscles, as described elsewhere⁵⁶. The muscle fibers were incubated with the fluorescent calcium probe FURA-2 for 45–60 min at 22°C in physiological solution containing 5 μM of the acetoxymethyl ester (AM) form of the dye mixed to 10% (v/v) Pluronic F-127 (Molecular Probes, Leiden, The Netherlands). A QuantiCell 900 integrated imaging system (VisiTech International Ltd) was used to acquire pairs of background-subtracted

images of the FURA-2 fluorescence emission (510 nm) excited at 340 nm and 380 nm. The equation used to transform fluorescence ratio in $[Ca^{2+}]_i$ values was $[Ca^{2+}]_i = (R - R_{min}) / (R_{max} - R) \cdot K_D \cdot \beta$, where R is the ratio of fluorescence excited at 340 nm to that excited at 380 nm; $K_D = 145$ nM; β , R_{min} and R_{max} were determined *in situ* in ionomycin-permeabilized muscle fibers. The cytosolic calcium response of muscle fibers to *in vitro* application of 40 mM caffeine was measured to evaluate calcium release from the sarcoplasmic reticulum.

Statistical analysis and Multivariate Statistical analysis: PCA and LDA algorithms. All data are expressed as the mean \pm SEM. Statistical analysis for direct comparison between two groups of data means was performed using unpaired Student's t-test, while multiple statistical comparison between groups was performed using ANOVA test, with Bonferroni's t test post hoc correction, allowing a better evaluation of intra- and inter-group variability (using Prism 7.0 Software, GraphPad). For the analysis of correlations between two parameters, Python 3.6, Scipy and Seaborn packages have been used and Pearson correlation coefficient and the 2-tailed p-value for testing non-correlation have been calculated. Multivariate analysis of gene expression dataset has been performed following the PCA-LDA analysis^{57,58}. For each animal 27 genes have been analyzed as normalized values ratio with house-keeping gene β -Actin (HK: Actb; target genes: Clc1, PKC Theta, PKC Alpha, Ryr1, Serca1, Serca2, CN, Bk, Kir6.2, Sur1, Surb2a, Sur2b, Nav1.4, Nmdar1, Ampar2, Murf1, Irisin, Notch1, TauT, Ampk, Ngf, Mstn, Achr1, Mhc2b, Mhc2x, Mhc2a, Mhc1). The starting data-frame consisted of a matrix with 30 rows (animals) and 27 columns (gene expression levels) with a total of 810 points. Because PCA and LDA algorithms suffer of the presence of big outliers in the dataset, first step of the pipeline has been their handling. So, the two biggest outliers onto genes that represents the major part of the variance in the system of data (ESD method, $p < 0.001$) have been removed and the resulting empty cells of table have been filled with the mean values of the mRNA's level of the groups to which they belong. The second step has been to standardize the gene expression dataset scaling the mean to 0 and the variance to unitary scale, this is done for each column. After that a PCA object has been trained by the use of the Scikit-learn class `sklearn.decomposition.PCA` setting the number of principal component computed up to 27 (the minor dimension of the dataset) and the `svd-solver` parameter to 'full', because the dataset has less than 500×500 dimension. In this way, the object PCA has been trained, taking as input, the consolidated and standardized dataset, computing than a linear dimensionality reduction using the Singular Value Decomposition solver. The subsequent step in the PCA-LDA pipeline was to perform 3 Fisher Linear Discriminant Analysis (LDA) of PC scores. The class `sklearn.discriminant_analysis` has been used to build a prototype classifier with a linear decision boundary using the Bayes' rule, starting from a matrix $n \times m$ and a vector containing group identifiers. The 3 LDA further reduced dataset's dimension starting the first three PC scores, to an single Linear Discriminant (LD) dimension, in a supervised manner, maximizing the variance between and minimizing the variance within classes. From each LDA a 1×3 vector with the LD coefficients of the 3 PC have been calculated. In the first LDA we obliged the classifier to find the LD that better separate MLC/SOD1^{G93A} mice from WT. In the second LDA the LD that better separate SOD1^{G93A} mice from the WT and in the third LDA the LD that better segregate MLC/SOD1^{G93A} mice from the SOD1^{G93A} ones. Finally, 3 vectors of LDA coefficients and a matrix containing the PCA loading weights of each genes have been obtained. Thus, the three discriminant lists of genes that separate the classes have been obtained multiplying the PCA loadings matrix with each transposed vector of LDA coefficients. Each multiplication gave as result, a vector of 27 PCA-LDA discriminant weights of genes analyzed. The absolute values of each element in these lists have been ordered in growing manner so the most important discriminant genes appeared at the bottom of the three lists of discriminant genes.

References

- Musarò, A. Understanding ALS: new therapeutic approaches. *FEBS J.* **280**, 4315–4322 (2013).
- Dobrowolny, G. *et al.* Skeletal Muscle Is a Primary Target of SOD1 G93A-Mediated Toxicity. *Cell Metabolism* **8**, 425–436 (2008).
- Dobrowolny, G., Aucello, M. & Musarò, A. Muscle atrophy induced by SOD1G93A expression does not involve the activation of caspase in the absence of denervation. *Skelet. Muscle* **1**(1), 3 (2011).
- Dobrowolny, G. *et al.* Muscle Expression of SOD1G93A Triggers the Dismantlement of Neuromuscular Junction via PKC-Theta. *Antioxid. Redox Signal.* **28**, 1105–1119 (2018).
- Wong, M. & Martin, L. J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. *Hum. Mol. Genet.* **19**, 2284–2302 (2010).
- Boillée, S., Vande Velde, C. & Cleveland, D. W. ALS: a disease of motor neurons and their nonneuronal neighbors. *Neuron* **52**, 39–59 (2006).
- Kalmar, B., Edet-Amana, E. & Greensmith, L. Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. *Amyotroph. Lateral. Scler.* **13**, 378–392 (2012).
- Dobrowolny, G. *et al.* Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. *J. Cell. Biol.* **168**, 193–199 (2005).
- Dadon-Nachum, M., Melamed, E. & Offen, D. The “dying-back” phenomenon of motor neurons in ALS. *J. Mol. Neurosci.* **43**, 470–477 (2011).
- Imbrici, P. *et al.* Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. *Front. Pharmacol.* **7**, 121 (2016).
- Desaphy, J.-F. *et al.* Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes. *Exp. Neurol.* **248**, 530–540 (2013).
- Pierno, S., De Luca, A., Beck, C. L., George, A. L. Jr. & Conte Camerino, D. Aging-associated down-regulation of ClC-1 expression in skeletal muscle: phenotypic-independent relation to the decrease of chloride conductance. *FEBS Lett.* **449**, 12–16 (1999).
- Camerino, G. M. *et al.* Protein kinase C theta (PKC θ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKC θ . *Pflugers Arch.* **466**, 2215–2228 (2014).
- Desaphy, J.-F., Carbonara, R., Costanza, T. & Conte Camerino, D. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs. *Exp. Neurol.* **255**, 96–102 (2014).
- Pierno, S. *et al.* An olive oil-derived antioxidant mixture ameliorates the age-related decline of skeletal muscle function. *Age (Dordr)* **36**, 73–88 (2014).
- Camerino, G. M. *et al.* Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study. *Front. Pharmacol.* **8**, 500 (2017).

17. Pierno, S. *et al.* Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing CIC-1 channel regulation and expression. *Br. J. Pharmacol.* **156**, 1206–1215 (2009).
18. Tricarico, D. & Camerino, D. C. ATP-sensitive K⁺ channels of skeletal muscle fibers from young adult and aged rats: possible involvement of thiol-dependent redox mechanisms in the age-related modifications of their biophysical and pharmacological properties. *Mol. Pharmacol.* **46**, 754–761 (1994).
19. Li, Y., Yu, W. P., Lin, C. W. & Chen, T. Y. Oxidation and reduction control of the inactivation gating of Torpedo CIC-0 chloride channels. *Biophys. J.* **88**, 3936–3945 (2005).
20. Vucic, S., Nicholson, G. A. & Kiernan, M. C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. *Brain* **131**, 1540–1550 (2008).
21. Roselli, F. & Caroni, P. Modeling. *Neuronal Vulnerability in ALS. Neuron* **83**, 758–760 (2014).
22. Oskarsson, B. *et al.* Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. *Muscle Nerve* **6**, <https://doi.org/10.1002/mus.26117> (2018).
23. Pierno, S. *et al.* Disuse of rat muscle *in vivo* reduces protein kinase C activity controlling the sarcolemma chloride conductance. *J. Physiol.* **584**, 983–995 (2007).
24. Tricarico, D. *et al.* Hybrid assemblies of ATP-sensitive K⁺ channels determine their muscle-type-dependent biophysical and pharmacological properties. *Proc. Natl. Acad. Sci. USA* **103**, 1118–1123 (2006).
25. Eftimie, R., Brenner, H. R. & Buonanno, A. Myogenin and MyoD join a family of skeletal muscle genes regulated by electrical activity. *Proc. Natl. Acad. Sci. USA* **88**, 1349–1353 (1991).
26. Palma, E. *et al.* Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. *Proc. Natl. Acad. Sci. USA* **113**, 3060–3065 (2016).
27. Park, K. H., Franciosi, S. & Leavitt, B. R. Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. *Nat. Commun.* **4**, 2906 (2013).
28. Doppler, K., Mittelbronn, M. & Bornemann, A. Myogenesis in human denervated muscle biopsies. *Muscle Nerve* **37**, 79–83 (2008).
29. Raffaello, A. *et al.* Denervation in murine fast-twitch muscle: short-term physiological changes and temporal expression profiling. *Physiol. Genomics* **25**, 60–74 (2006).
30. Pierno, S. *et al.* Change of chloride ion channel conductance is an early event of slow-to-fast fibre type transition during unloading-induced muscle disuse. *Brain* **125**, 1510–1521 (2002).
31. Camerino, G. M. *et al.* Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. *Toxicol. Appl. Pharmacol.* **306**, 36–46 (2016).
32. Mele, A. *et al.* Dual response of the KATP channels to staurosporine: A novel role of SUR2B, SUR1 and Kir6.2 subunits in the regulation of the atrophy in different skeletal muscle phenotypes. *Biochem. Pharmacol.* **91**, 266–275 (2014).
33. Dufresne, S. S. *et al.* Muscle RANK is a key regulator of Ca²⁺ storage, SERCA activity, and function of fast-twitch skeletal muscles. *Am. J. Physiol. Cell Physiol.* **310**, C663–C672 (2016).
34. Dupuis, L. *et al.* Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. *Proc. Natl. Acad. Sci. USA* **101**, 11159–11164 (2004).
35. Le Masson, G., Przedborski, S. & Abbott, L. F. A computational model of motor neuron degeneration. *Neuron* **83**, 975–988 (2014).
36. Beqollari, D. *et al.* Progressive impairment of CaV1.1 function in the skeletal muscle of mice expressing a mutant type 1 Cu/Zn superoxide dismutase (G93A) linked to amyotrophic lateral sclerosis. *Skelet. Muscle* **6**, 24 (2016).
37. Reza, M. M. *et al.* Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy. *Nat. Commun.* **8**, 1104 (2017).
38. Personius, K. E., Slusher, B. S. & Udin, S. B. Neuromuscular NMDA Receptors Modulate Developmental Synapse Elimination. *J. Neurosci.* **36**, 8783–8789 (2016).
39. Petrov, K. A. *et al.* Regulation of acetylcholinesterase activity by nitric oxide in rat neuromuscular junction via N-methyl-D-aspartate receptor activation. *Eur. J. Neurosci.* **37**, 181–189 (2013).
40. Jenkins, M. A. & Traynelis, S. F. PKC phosphorylates GluA1-Ser831 to enhance AMPA receptor conductance. *Channels (Austin)* **6**, 60–64 (2012).
41. Cosentino-Gomes, D., Rocco-Machado, N. & Meyer-Fernandes, J. R. Cell signaling through protein kinase C oxidation and activation. *Int. J. Mol. Sci.* **13**, 10697–10721 (2012).
42. Lanuza, M. A. *et al.* Pertussis toxin-sensitive G-protein and protein kinase C activity are involved in normal synapse elimination in the neonatal rat muscle. *J. Neurosci. Res.* **63**, 330–340 (2001).
43. Bloch-Gallego, E. Mechanisms controlling neuromuscular junction stability. *Cell. Mol. Life Sci.* **72**, 1029–1043 (2015).
44. Dobrowolny, G. *et al.* Metabolic changes associated with muscle expression of SOD1G93A. *Front. Physiol.* **9**, 831 (2018).
45. De Luca, A., Pierno, S., Liantonio, A., Camerino, C. & Conte Camerino, D. Phosphorylation and IGF-1-mediated dephosphorylation pathways control the activity and the pharmacological properties of skeletal muscle chloride channels. *Br. J. Pharmacol.* **125**, 477–482 (1998).
46. De Luca, A., Pierno, S., Camerino, C., Cocchi, D. & Camerino, D. C. Higher content of insulin-like growth factor-I in dystrophic mdx mouse: potential role in the spontaneous regeneration through an electrophysiological investigation of muscle function. *Neuromuscul. Disord.* **9**, 11–18 (1999).
47. Tricarico, D., Barbieri, M. & Camerino, D. C. Acetazolamide opens the muscular KCa2⁺ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. *Ann. Neurol.* **48**, 304–312 (2000).
48. Eguchi, H. *et al.* Acetazolamide acts directly on the human skeletal muscle chloride channel. *Muscle Nerve* **34**, 292–297 (2006).
49. Liu, X., Lu, D., Bowser, R. & Liu, J. Expression of Carbonic Anhydrase I in Motor Neurons and Alterations in ALS. *Int. J. Mol. Sci.* **17**, 1820, <https://doi.org/10.3390/ijms17111820> (2016).
50. Phillips, C., Baktir, M. A., Srivatsan, M. & Salehi, A. Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. *Front. Cell. Neurosci.* **8**, 170 (2014).
51. Zsuga, J., Tajti, G., Papp, C., Juhasz, B. & Gesztelyi, R. FNDC5/irisin, a molecular target for boosting reward-related learning and motivation. *Med. Hypotheses* **90**, 23–28 (2016).
52. Hatzipetros, T. *et al.* Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS. *J. Vis. Exp. Oct* **6** (104), <https://doi.org/10.3791/53257> (2015).
53. Mele, A. *et al.* *In vivo* longitudinal study of rodent skeletal muscle atrophy using ultrasonography. *Sci. Rep.* **6**, 20061, <https://doi.org/10.1038/srep20061> (2016).
54. Desaphy, J.-F. *et al.* Antioxidant treatment of hindlimb-unloaded mouse counteracts fiber type transition but not atrophy of disused muscles. *Pharmacol. Res.* **61**, 553–563 (2010).
55. Desaphy, J.-F., Pierno, S., De Luca, A., Didonna, P. & Camerino, D. C. Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders. *Mol. Pharmacol.* **63**, 659–670 (2003).
56. Frayssé, B. *et al.* Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle. *FASEB J.* **17**, 1916–1918 (2003).
57. Gambara, G. *et al.* Gene Expression Profiling in Slow-Type Calf Soleus Muscle of 30 Days Space-Flown Mice. *PLoS One* **12**, e0169314 (2017).
58. Ringner, M. What is principal component analysis? *Nat Biotechnol.* **26**, 303–304 (2008).

Acknowledgements

This work was supported by grants from University of Bari, Es. Fin. 2012, Fondi Ateneo 2012 to SP and Fondi Ateneo 2015 to MDB. This work was also supported by the Agenzia Spaziale Italiana (AM²).

Author Contributions

G.M.C., A.F., S.P. designed the study; G.M.C., A.F., E.C., M.D.B., A.M., A.L., D.T., N.T., G.D., S.P. performed the experiments, analyzed the data and critically interpreted results; AM², J.F.D., A.D.L. contributed ideas and critically revised the manuscript; SP wrote the final version of the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-39676-3>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019